Pulse Biosciences Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Investigational Device Exemption $(IDE)$, allowing the company to initiate the nPulse Cardiac Catheter Ablation System Study (NANOPULSE-AF) for the treatment of paroxysmal atrial fibrillation $(PAF)$. The approval enables Pulse Biosciences to move forward with clinical evaluation of its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology in the United States. No other organizations are mentioned as recipients of this regulatory approval.